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The hypoxia-regulated alternative TrkAIII splice variant expressed by human neuroblastomas exhibits
oncogenic potential, driven by in-frame exon 6 and 7 alternative splicing, leading to omission of the receptor
extracellular immunoglobulin C1 domain and several N-glycosylation sites. Here, we show that the TrkAIII
oncogene promotes genetic instability by interacting with and exhibiting catalytic activity at the centrosome.
This function depends upon intracellular TrkAIII accumulation and spontaneous interphase-restricted acti-
vation, in cytoplasmic tyrosine kinase (tk) domain orientation, predominantly within structures that closely
associate with the fully assembled endoplasmic reticulum intermediate compartment and Golgi network. This
facilitates TrkAIII tk-mediated binding of !-tubulin, which is regulated by endogenous protein tyrosine
phosphatases and geldanamycin-sensitive interaction with Hsp90, paving the way for TrkAIII recruitment to
the centrosome. At the centrosome, TrkAIII differentially phosphorylates several centrosome-associated com-
ponents, increases centrosome interaction with polo kinase 4, and decreases centrosome interaction with
separase, the net results of which are centrosome amplification and increased genetic instability. The data
characterize TrkAIII as a novel internal membrane-associated centrosome kinase, unveiling an important
alternative mechanism to “classical” cell surface oncogenic receptor tk signaling through which stress-
regulated alternative TrkAIII splicing influences the oncogenic process.
Alternative splicing is fundamental for differential protein ex-
pression from the same gene and not only increases the pro-
teomic complexity of higher organisms (29) but is also involved in
cancer pathogenesis, activating several oncogenes and inactivat-
ing several oncosuppressors (17).
The neurotrophin receptor tropomyosin-related kinase A
(TrkA) is among the proto-oncogenes activated by alternative
splicing, with a novel hypoxia-regulated oncogenic alternative
TrkAIII splice variant recently identified in advanced-stage
human neuroblastomas (NB) and primary glioblastomas (44,
45). In contrast to wild-type TrkAI/TrkAII, the expression of
which is associated with better prognosis for NB, induces NB
cell differentiation, exhibits a tumor suppressor function in NB
models in vivo (9, 19, 22, 30, 44, 45), and may regulate both
spontaneous and therapy-induced NB regression (30), TrkAIII
is expressed by more-advanced-stage NB and exhibits onco-
genic activity in NB models (44, 45). This has challenged the
hypothesis of an exclusively tumor-suppressing function for
TrkA in NB by providing a way through which tumor-suppress-
ing signals from TrkA can be converted to oncogenic signals
from TrkAIII during tumor progression.
The oncogenic potential of TrkAIII, characterized by NIH
3T3 cell transforming and NB xenograft primary and meta-
static tumor-promoting activity (44, 45), is driven by in-frame
alternative splicing of exons 6 and 7. This results in the omis-
sion of the receptor extracellular immunoglobulin C1 (Ig C1)
Ig-like domain and several N-glycosylation sites important in
regulating TrkA cell surface expression and preventing ligand-
independent activation (2, 44, 45, 48). As a consequence, and
unlike TrkAI and TrkAII, TrkAIII is not expressed at the cell
surface but accumulates in the intracellular membrane com-
partment, within which it exhibits spontaneous tyrosine kinase
(tk) and phosphoinositol-3 kinase (PI3K) activity and induces
chronic signaling through PI3K/Akt/NF-"B but not Ras/mito-
gen-activated protein kinase (MAPK), inducing a more stress-
resistant, angiogenic, and tumorigenic NB cell phenotype (44,
45). This differs from ligand-activated cell surface TrkA, which
signals transiently through Ras/MAPK in NB cells to induce
differentiation and a less angiogenic and tumorigenic NB cell
phenotype (9, 19, 22, 30, 44, 45). This difference in signaling
provides a potential basis for the opposing tumor-suppressing
and oncogenic effects of alternative TrkA splice variants, which
may not only depend upon the dislocation of TrkAIII from cell
surface caveolae, which are the sites of TrkAI expression and
Ras/MAPK signal initiation (45, 48), but also TrkAIII-associ-
ated PI3K activity below the Ras/MAPK activation threshold
and/or TrkAIII-associated PI3K antagonism of Raf/MEK/ex-
tracellular signal-regulated kinase signaling (44). Signal trans-
duction from intracellular TrkAIII bears close resemblance to
the transient signaling through PI3K/Akt/NF-"B but not Ras/
MAPK induced by A2a adenosine receptor/c-Src-mediated
transactivation of immature TrkAI within the Golgi network
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(GN) (37), suggesting that the intracellular localization of
TrkAIII is a critical determinant of both differential signaling and
oncogenic potential.
Intracellular nonnuclear membranes are separated into the
endoplasmic reticulum (ER), ER-GN intermediate compart-
ment (ERGIC), GN, and transport vesicles, which assemble
around, integrate, and interact with the centrosome (38). The
centrosome, comprised of two centrioles embedded within a
pericentriolar matrix of over 100 proteins, including #-tubulin,
acts as the major microtubule-organizing center and orches-
trates the assembly, organization, and integration of the ER,
ERGIC, GN, and associated vesicles (38). The centrosome
also maintains genomic integrity by duplicating once per cell
cycle S phase, ensuring bipolar mitotic spindle formation, ac-
curate chromosome segregation, and the inheritance of a sin-
gle centrosome by each daughter cell (23).
Centrosome duplication is tightly regulated by protein kinases
Aurora-A and -B, polo kinases 1 and 4 (Plk-1 and Plk-4), Cdk2,
PI3K, Zyg-1, Syk, Nek2, regulators Pin-1 and separase, and re-
lated phosphatases (11, 12, 18, 31, 42, 47, 53). The deregulation of
centrosome duplication leads to centrosome amplification and
subsequently to aberrant mitotic spindle formation, which pro-
motes aneuploidy and polyploidy. Thesemanifestations of genetic
instability represent hallmarks of malignancy and drive tumor
progression by promoting a more malignant phenotype (11, 12,
26, 35, 49). Centrosome amplification and subsequent genetic
instability are induced by kinases that target the centrosome, the
loss of centrosome-associated kinase inhibitors, altered levels of
centrosome-associated regulators, and oncosuppressor inactiva-
tion (6, 7, 11, 12, 35, 40, 42, 49, 53).
The localization of TrkAIII to internal membranes, as a
prerequisite for oncogenic activity (44, 45), makes identifica-
tion of the membrane context within which TrkAIII exhibits
activity and novel substrate interactions within this environ-
ment important in elucidating how TrkAIII exerts oncogenic
potential. In the present study, we unveil a novel oncogenic
mechanism for TrkAIII by demonstrating that TrkAIII activa-
tion within membranes that associate closely with the assem-
bled ER/ERGIC/GN facilitates recruitment to the centro-
some, results in centrosome amplification, and promotes
genetic instability.
MATERIALS AND METHODS
Cell lines and expression vectors. TrkAI and TrkAIII expression vectors
andstably pcDNA-, TrkAI-, and TrkAIII-transfected SH-SY5Y and NIH 3T3
cell lines have been described previously (44). Green fluorescent protein (GFP)-
centrin-expressing HeLa cells (34) were supplied by L. Di Marcotullio (Univer-
sity of Rome La Sapienza). Cell lines were grown in recommended medium
(RPMI or Dulbecco’s modified Eagle’s medium), supplemented with 10% fetal
calf serum and appropriate antibiotics (phleomycin [Zeocin], penicillin, and
streptomycin). The kinase-dead mutant kd-muTrkAIII pcDNA3.1Zeo expression
vector bearing phenylalanine substitutions of tk loop tyrosines Y670, Y674, and
Y675, was constructed from the pcDNA TrkAIII (44) by replacing a 370-bp
EcoRV digestion fragment with a PCR product generated using the Y670F/
Y674F/Y675F mutant forward primer 5$-AGCAGGGATATCTtCAGCACCGA
CTttTtCCGTGTG-3$ and the reverse primer 5$-GCCACTGTGCTGGATATCT
GCAGAATTC-3$ (lowercase letters indicate mutated nucleotides). SH-SY5Y cells
stably transfected with kd-muTrkAIII were obtained as previously described for
the generation of stably TrkAI- and TrkAIII-transfected SH-SY5Y cells (44).
Reagents and antibodies. Cell culture reagents, sodium orthovanadate, brefel-
din A (BFA), geldanamycin (GA), cytochalasin D, nocodazole (NZ), SCH-
58621, proteinase inhibitor cocktail, bis-benzimide trihydrochloride, propidium
iodide, iohexol (Histodenz), nerve growth factor (NGF), polyclonal anti-
ERGIC53, anti-#-tubulin, and anti-NGF-neutralizing antibodies were from
Sigma-Aldrich (St. Louis, MO). The pan-Trk inhibitor CEP-701 (4) was supplied
by Cephalon Inc. (West Chester, PA), and the c-Src inhibitor GCP77675 was
from Novartis Pharma (28). Anti-human Cep170 antibody was supplied by G.
Guarguaglini (University of Rome La Sapienza, Rome, Italy) (14). The mono-
clonal anti-%-tubulin, anti-phosphotyrosine (pY99), and anticalnexin antibodies
and the polyclonal anti-carboxyl terminal TrkA (C14) and anti-phospho-Y490
TrkA antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). The
monoclonal anti-human extracellular domain TrkA antibody MRG12 was from
Alexis Biochemicals (Plymouth Meeting, PA). The polyclonal antiactin, anti-
TGN46, and antiseparase antibodies and monoclonal anti-Nedd-1 and anti-
GMAP-210 antibodies were from Abcam (Cambridge, United Kingdom). The
monoclonal anti-mannosidase II antibody was from Novus Biologicals (Littleton,
CO), monoclonal anti-GM130 antibody was from BD Bioscience (San Jose, CA),
and polyclonal anti-Plk4 antibody was from Cell Signaling (Danvers, MA). Flu-
orescein isothiocyanate- and Texas Red-conjugated secondary anti-mouse and
anti-rabbit IgG antibodies were from Jackson ImmunoResearch (Bar Harbor, ME).
RT-PCR conditions and primers. Reverse transcription (RT) reactions were
performed using mRNA (1 &g) and a Moloney murine leukemia virus reverse
transcriptase kit according to the manufacturer’s instructions (Life Technologies,
Inc., Paisley, United Kingdom), in a final volume of 20 &l for 45 min at 42°C.
Aliquots (1 &l) of diluted RT reaction mix were subjected to 35 cycles (1 min at
94°C, 1 min at 55°C, and 2 min at 72°C) of PCR amplification using the following
specific primers: for TrkAI/TrkAII and TrkAIII, forward primer 5$-AACCTCA
CCATCGTGAAGAGTGGT-3$ and reverse primer 5$-GGTTGAACTCGAAA
GGGTTGTCCA-3$; for Plk-4, forward primer 5$-GCCAAGGACCTTATTCA
CCAGT-3$ and reverse primer 5$-GTTGGCATTGTTGTCTGTGGGT-3$; for
XBP-1, forward primer 5$-TTACGAGAGAAAACTCATGGC-3$ and reverse
primer 5$-GGGTCCAAGTTGTCCAGAATGG-3$; and for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), forward primer 5$-CGGAGTCAACGGA
TTTGGTCGTAT-3$ and reverse primer 5$-AGCCTTCTCCATGGTGGTGAA
GAC-3$. These primers were used to control RNA quality and quantity. RT-
PCR products were resolved by 1.5% agarose gel electrophoresis.
Ultracentrifugation of intracellular membranes. Intracellular nucleus-free
membranes were purified from exponentially growing SH-SY5Y transfectants
and separated into ER and non-ER fractions as previously described (52).
Briefly, cells were washed and scraped into cold PBS, washed in homogenization
buffer (130 mM KCl, 5 mM MgCl2, 25 mM Tris-HCl, pH 7.3), and homogenized
in 500 &l homogenization buffer containing proteinase inhibitor cocktail [1 mM
4-(2-amino-ethyl)benzenesulfonylfluoride hydrochloride, 20 &M leupeptin, 15
&M pepstatin, 15 &M chymostatin]. Homogenates were centrifuged for 5 min at
1,000 ' g at 4°C, and supernatants were collected and recentrifuged at 1,000 '
g for 5 min at 4°C to give the postnuclear supernatant. The postnuclear super-
natant was adjusted to 500 &l in homogenization buffer and layered on top of a
step gradient composed, from bottom to top, of 500 &l of 40%, 1 ml of 20%
iohexol, 1 ml of 17.5% iohexol, and 1 ml of 15% iohexol (Sigma-Aldrich), diluted
in homogenization buffer. Gradients were subjected to ultracentrifugation at 4°C
in an SW 55 Ti rotor for 60 min at 100,000 ' g, and 500-&l fractions, collected
from top to bottom, were mixed with 125 &l of 5' detergent buffer (5% NP-40,
2.5% deoxycholate, 0.5% sodium dodecyl sulfate [SDS], 250 mM Tris-HCl, pH
8.0) and either subjected to immunoprecipitation (IP) with anti-TrkA (C14)
antibody or separated by Western blotting to identify fractions positive for the
GN and ER markers as previously described (52). Immunoprecipitates were
washed once with radioimmunoprecipitation assay buffer (1% NP-40, 0.5% de-
oxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0), two times with
high-salt buffer (0.2% SDS, 1% Triton X-100 [TX100], 5 mM EDTA, 500 mM
NaCl, 50 mM Tris-HCl, pH 8.0), and once with TEN buffer (50 mM Tris-HCl,
pH 8.0, 5 mM EDTA, 150 mM NaCl), prior to analysis by reducing SDS-
polyacrylamide gel electrophoresis (PAGE)/Western blotting.
Rabbit enolase kinase assay. Kinase assays were performed as previously
described (25). Briefly, acid-denatured rabbit muscle enolase (5 &g; Sigma) was
added as the substrate to 50 &l of reaction buffer (10 mM HEPES, pH 7.4, 5 mM
MgCl2, 10 &M ATP, 100 &M sodium orthovanadate) containing 10 to 20 &Ci
[#-32P]ATP (Amersham) and anti-TrkA IP products. Reaction mixes were incu-
bated at 30°C for 15 min, and reactions were terminated by the addition of 50 ml
of 2' SDS-PAGE sample buffer (120 mM Tris, pH 6.8, 20% glycerol, 2% SDS)
containing 100 mM dithiothreitol. Samples were heated to 90°C and subjected to
10% SDS-PAGE. Dried gels were exposed to Kodak XAR film with an inten-
sifying screen at (70°C for a minimum of 7 days.
Sucrose density gradient ultracentrifugation purification of centrosomes.
Briefly, cells were preincubated with cytochalasin D (1 &g/ml) and NZ (0.1 &M)
for 1 h at 37°C and then harvested by trypsinization. Harvested cells (1 ' 107 to
3 ' 107) were washed in phosphate-buffered saline (PBS) and lysed in 5 ml of
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lysis buffer (1 mM HEPES, pH 7.2, 0.5% NP-40, 0.5 mM MgCl2, 0.1% 2-mer-
captoethanol) containing EDTA-free proteinase inhibitor cocktail (Boeringer
Mannheim) and the phosphatase inhibitors sodium fluoride (50 mM) and so-
dium orthovanadate (1 mM). Swollen nuclei and chromatin aggregates were
removed by centrifugation at 2,500 ' g for 10 min at 4°C, and supernatants were
filtered through 40-&m mesh nylon filters. Supernatants were adjusted to 10 mM
HEPES, 2 U/ml DNase I (Boeringer Mannheim) was added, and the superna-
tants were incubated on ice for 30 min. Lysates were underlaid with 500 &l of
60% sucrose solution in 10 mM PIPES [piperazine-N,N$-bis(2-ethanesulfonic
acid), pH 7.2], 0.1% Triton X-100, and 0.1% 2-mercaptoethanol, and centro-
somes were sedimented into the sucrose cushion by centrifugation at 10,000 ' g
for 30 min at 4°C. The bottom 1.5 ml of the sucrose cushion was taken, resus-
pended, and overlaid onto a discontinuous gradient composed of 500 &l of 70%
sucrose, 300 &l of 50% sucrose, and 300 &l of 40% sucrose solution in the
aforementioned diluent. Gradients were ultracentrifuged at 120,000 ' g for 1 h
at 4°C, and seven 200-&l fractions were taken from bottom to top, with the
remaining 1 ml taken as fraction 8. Each fraction was diluted to 1 ml with 10 mM
PIPES buffer (pH 7.2) and centrifuged at 15,000' g for 10 min at 4°C. Reducing
SDS-PAGE sample buffer was added to pellets, and each fraction was subjected
to SDS-PAGE/Western blotting. Anti-#-tubulin antibody was used to identify
centrosome-containing fractions as previously described (42).
GFP-centrin-expressing HeLa cell centrosome amplification assay. Stably
GFP-centrin-transfected HeLa cells (5' 104) (34), were seeded onto Nunc glass
chamber slides (Sigma-Aldrich, MO) and grown for 24 h to 50% confluence prior
to transient transfection with 1 &g expression vector in 3 &l of Fugene-6 trans-
fection reagent (Invitrogen, San Giuliano, Italy) for 6 h at 37°C. At 6 h, trans-
fection medium was replaced with complete culture medium and cells grown for
a further 48 h at 37°C. At 48 h, cultures were washed in prewarmed PBS and
incubated for 1 h at 37°C in PBS containing 5 &g/ml Hoechst 33342 (Sigma-
Aldrich). Slides were rinsed in PBS, fixed in 10% formalin, and permeabilized in
100% cold methanol for 6 min at (20°C. Nonspecific binding sites were blocked
in 1% bovine serum albumin in PBS–0.03% TX100 for 30 min, and slides were
incubated for 2 h with primary anti-TrkA antibody (C14) diluted in blocking
solution, rinsed in PBS–0.03% TX100, and then incubated for 1 h in secondary
affinity-purified Texas Red-conjugated goat anti-rabbit IgG (Jackson Immuno-
Research) diluted in blocking solution, as recommended by the manufacturer.
Following incubation, slides were washed in PBS–0.03% TX100 and mounted in
VectorMount and examined under a Zeiss Axioplan 2 fluorescence microscope,
armed with a digital camera system and Leica M500 Image Manager software.
TrkAIII PNA synthesis. Fmoc (9-fluorenylmethoxy carbonyl; benzhydryloxy-
carbonyl) peptide nucleic acid (PNA) monomers were from (PRIMM, Milan,
Italy); amino acids, activators, and resins were from Novabiochem (Nottingham,
United Kingdom); acetonitrile was from Riedel-deHae¨n (Seelze, Germany); and
dry N,N-dimethylformamide (DMF) was from Lab-Scan (Stillorgan, Ireland). All
other reagents were from Fluka (St. Louis, MO). Solid-phase PNA synthesis was
performed on an Expedite 8909 nucleic acid synthesis system (ABI). Liquid
chromatography-mass spectrometry analyses were performed on a Thermo
Finnigan liquid chromatography-mass spectrometry system with an electrospray
source (MSQ) on a Phenomenex Jupiter 5-&m C18 300-Å (150- by 4.6-mm)
column. A Phenomenex Jupiter 10-&m Proteo 90-Å (250- by 10-mm) column was
used for purification on a semipreparative scale. Peptides were synthesized on a
phenylalanine ammonia lyase-polyethylene glycol resin (0.16 mol/g). Briefly,
amino acids (10 eq) were preactivated in 1-hydroxy benzotriazole–N-[(1H-ben-
zitriazol-1yl)(dimethylamino)methylene]-N-methylmethanaminium hexafluoro-
phosphate N-oxide (9.8 eq; 0.5 M) in DMF and N,N-diisopropylethylamine
(DIPEA) (30 eq) and coupled for 15 min. The resin was washed with DMF (two
flow washes, 25-s each), and capping was performed in acetic anhydride-DIPEA-
DMF (15:15:70, vol/vol/vol) for 5 min, followed by two 25-s flow washes with
DMF. Peptides were deprotected in piperidine-DMF (20:80, vol/vol) for 5 min,
and resin was washed with DMF (two flow washes, 25-s each) and transferred
into a small reaction vessel for PNA oligomer assembly. PNAs were synthesized
on a 2-&mol scale in an Expedite 8909 synthesizer by using standard protocols.
Double coupling was carried out on polypurine tracts (doubly coupled bases are
underlined in the sequences). At the end of the synthesis, resins were washed
with dichloromethane and vacuum dried. PNA and the peptide-PNA conjugates
(16) were cleaved from the resin and deprotected in a solution of trifluoroacetic
acid (TFA)–triisopropylsilane–m-cresol (78:2:20) for 90 min at room tempera-
ture to obtain KKAA-TrkAIII [(KKAA)4-GGCCGGGACACA], which was pu-
rified by high-performance liquid chromatography in a 5-min gradient of 7%
isocratic water (0.1% TFA), followed by a 30-min gradient of acetonitrile (0.1%
TFA) in water (0.1% TFA) from 7 to 35%, eluted at 22.2 min, identified by
electrospray mass analysis, and lyophilized three times to remove excess TFA.
IP and Western blots. Cells were extracted on ice in lysis buffer (PBS containing
0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, 1 mM sodium orthovanadate, 1
mM phenylmethylsulfonyl fluoride, 1 &g/ml of pepstatin A, aprotinin), and protein
concentrations were calculated by the Bradford assay (Sigma-Aldrich). Extract ali-
quots (200 to 500 &g) were precleared with 1 &g of preimmune IgG (1 h at 4°C) and
20 &l of protein A Sepharose (Fast Flow; Sigma-Aldrich) for 20 min at 4°C and 200
to 500 &g of precleared extract incubated with primary antibody (0.1 to 1.0 &g
antibody/500 &g protein extract) for 2 to 16 h at 4°C. Following incubation, 20 &l of
protein A Sepharose (Fast Flow; Sigma-Aldrich) in lysis buffer was added, and
reaction mixes were incubated for 30 min at 4°C. Protein A Sepharose-IgG conju-
gates were collected by centrifugation (10,000' g for 5 min), washed three times in
lysis buffer, resuspended in SDS-PAGE sample buffer, and subjected to reducing
SDS-PAGE/Western blotting. Proteins, transblotted by electrophoresis onto Hy-
bond C! nitrocellulose membranes (Amersham International, United Kingdom),
were air dried, and nonspecific protein binding sites were blocked by incubation for
2 h in 5% nonfat milk in Tris-buffered saline and membranes and then incubated
with primary antibody at the recommended dilution in blocking solution for 2 to 16 h
at 4°C. Blots were washed in Tris-buffered saline and incubated with secondary
horseradish peroxidase-conjugated antibody diluted in blocking solution, and immu-
noreactive species were detected by a chemiluminescence reaction (Amersham
International, Bedford, United Kingdom).
Cell cycle and cell surface TrkA fluorescence-activated cell sorter (FACS)
analysis. Cells were recovered, washed twice in ice-cold PBS, and fixed in 70%
ethanol at 4°C for at least 30 min, washed twice in ice-cold PBS, stained with 50
&g/ml of propidium iodide solution containing 25 &g/ml of RNase A and incu-
bated in the dark at room temperature for 30 min. Cell cycle phase distribution
was analyzed by flow cytometry (FACScan flow cytometry; Becton Dickinson
Immunocytometry Systems, San Jose, CA), and data from 10,000 events per
sample were analyzed using Modfit LT for Mac version 3.0 cell cycle analysis
software. For cell surface TrkA expression in nonpermeabilized cells, cells were
detached at 4°C with PBS-EDTA, resuspended in calcium and magnesium-free
PBS, dispersed into 12 75-mm tubes (0.5 ' 106 cells per tube), centrifuged, and
incubated with 0.5 &g of anti-TrkA MGR12 monoclonal antibody or 0.5 &g of
normal mouse IgG in 100 &l PBS at 4°C for 1 h. After being washed with PBS,
cells were incubated with fluorescein isothiocyanate-conjugated goat anti-mouse
IgG (Sigma; diluted 1:128 in PBS) at 4°C for 45 min, washed in PBS, resuspended
in 500 &l PBS, and analyzed in a FACScan analyser (Becton Dickinson).
FIG. 1. TrkAIII differs from TrkAI in intracellular membrane distribution. (A) Indirect IF demonstrating TrkAI (green, upper-left panel) and
TrkAIII (green, upper-right panel) expression in respective stably transfected SH-SY5Y cells; GM130 (red), TrkAI (green), and merged
TrkAI/GM130 (orange/yellow) expressions in a representative TrkAI SH-SY5Y transfectant (three lower-left panels) and GM130 (red), TrkAIII
(green), and merged TrkAIII/GM130 (orange/yellow) expressions in a representative TrkAIII SH-SY5Y transfectant (three lower-right panels).
Bar ) 50 &m. (B) FACS analysis demonstrating cell surface immunoreactivity of nonpermeabilized (nonperm) TrkAI but not nonpermeabilized
TrkAIII NIH 3T3 transfectants to MGR-12 anti-TrkA monoclonal antibody (pink line) relative to immunoreactivity to preimmune IgG (black
line). Phase-contrast micrographs (middle two panels) comparing morphologies plus indirect IF (bottom panels) comparing TrkAI and TrkAIII
expressions (green) in respective TrkAI and TrkAIII NIH 3T3 transfectants. Bar ) 50 &M. (C) Western blots demonstrating GM130, TGN46,
COP I, COP II, ERGIC53, and calnexin distributions in ultracentrifugation-fractionated intracellular nonnuclear membranes from TrkAI (left
panels) and TrkAIII (right panels) SH-SY5Y transfectants. (D) IP/Western blots demonstrating the distributions of TrkAI and TrkAIII,
phosphorylation statuses, and coimmunoprecipitations of Grp78/BiP and calnexin in ultracentrifugation-fractionated membranes from TrkAI (left
panels) and TrkAIII (right panels) SH-SY5Y transfectants. IgGs in immunoprecipitates are shown as loading controls. (E) IP/Western blots
demonstrating alternatively folded TrkAIII (arrow) in calnexin-positive ER fractions (lanes 7 and 8) under nonreducing conditions (lower panel)
but not under reducing conditions (upper panel).
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FIG. 2. TrkAIII is activated during interphase within ER/ERGIC/GN-associated structures. (A) Indirect IF demonstrating no tyrosine
phosphorylation (pTyr; not detected) associated with TrkAI (green) in interphase TrkAI SH-SY5Y transfectants (bar ) 50 &m). (B) Indirect IF
demonstrating TrkAIII expression (green), tyrosine phosphorylation (red; pTyr), merged pTyr/TrkAIII expression (orange/yellow), and Hoechst-
stained chromatin (light blue) in SH-SY5Y transfectants during interphase, prometaphase, metaphase, anaphase, telophase, and postcytokinesis.
(C) The top panels show indirect IF demonstrating merged (yellow/orange) GM130 (red) and TrkAIII (green) expression (leftmost panel),
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IF. Cells grown on Nunc glass chamber slides (Sigma-Aldrich) were washed in
PBS, fixed in 96% ethanol–3% glacial acetic acid, and processed for indirect
immunofluorescence (IF). Slides were incubated for 1 h in blocking solution (1%
bovine serum albumin in PBS–0.03% TX100) and then for 2 to 16 h with primary
antibody in blocking solution at room temperature. Slides were washed three
times in PBS–0.03% TX100, then incubated with secondary fluorochrome-con-
jugated antibody diluted in blocking solution for 1 h at room temperature, and
then washed in PBS–0.03% TX100 and mounted using VectorMount. IF images
were obtained using a Zeiss Axioplan 2 fluorescence microscope with a digital
camera and Leica M500 Image Manager software.
Metaphase spreads and SCE. Cells treated for 2 h with colcemid (0.5 &g/ml)
(Sigma-Aldrich, MO) were harvested by trypsinization, and metaphase spreads
were prepared by swelling in hypotonic KCl solution (0.57%) for 10 min at 37°C.
After treatment, the cells, fixed in 3:1 methanol-acetic acid, were washed twice in
fresh fixative, and aliquots were dropped onto glass sides and air dried. For sister
chromatid exchange (SCE), cells were grown in the presence of 10 &M 5-bro-
modeoxyuridine (Sigma-Aldrich) in the dark for 48 h prior to colcemid treatment
and processed as described above, with the exception that air-dried slides were
aged for 3 days. Aged slides were incubated with 5 &g/ml Hoechst 33258 (Sigma-
Aldrich) for 10 min, rinsed in water, air dried, covered with 2' SSC (1' SSC is
0.15 M NaCl plus 0.015 M sodium citrate; pH. 7), and irradiated with a mixture
of long- and short-wave UV light at a distance of 20 cm for 2 h in the dark at
room temperature. Slides were then incubated in 2' SSC (pH 7) for 2 h at 60 to
65°C, rinsed in water, and air dried. Air-dried slides were stained with 2%
Giemsa stain for 15 min, rinsed in water, air dried, passed through xylene, and
mounted in Depex medium. Metaphase spreads and SCE were assessed by light
microscopy using a Zeiss Axioplan 2 microscope with a digital camera and Leica
M500 Image Manager software.
RESULTS
TrkAIII localizes to ER/ERGIC/GN membranes. Indirect IF
demonstrated predominant expression of TrkAI at the cell
surface and within the GN in stable TrkAI SH-SY5Y transfec-
tants (Fig. 1A, upper-left panel). The GN localization of TrkAI
was confirmed by overlapping expression with the cis-GN
marker GM130 (Fig. 1A, lower-left panels). In contrast to
TrkAI, TrkAIII expressed by stable TrkAIII SH-SY5Y trans-
fectants was not detected at the cell surface and accumulated
within the intracellular compartment (Fig. 1A, upper-right panel)
(44) but did not localize exclusively to the GM130-positive GN
(Fig. 1A, lower-right panels). For nonpermeabilized stable
NIH 3T3 transfectants, FACS analysis using an anti-TrkA ex-
tracellular domain monoclonal MGR12 specific for both TrkAI
and TrkAIII, which detects cell surface TrkAI but not TrkAIII
in stable SH-SY5Y transfectants (45), also confirmed cell sur-
face TrkAI but not TrkAIII expression (Fig. 1B, top panels).
Cell surface TrkAI expression in NIH 3T3 transfectants de-
tected by indirect IF was less evident at intercellular junctions
than that detected in SH-SY5Y transfectants (compare Fig.
1B, lower-left panel, and A, upper-left panel). This may reflect
the high degree of intercellular association exhibited by SH-
SY5Y cells (Fig. 1A) relative to that exhibited by NIH 3T3 cells
(Fig. 1B, lower four panels), which concentrates cell surface
TrkAI to intercellular junctions, facilitating detection (Fig.
1A). Alternatively, less TrkAI may reach the NIH 3T3 cell
surface. Indirect IF also detected similarity in intracellular
GN-localized TrkAI in SH-SY5Y transfectants (Fig. 1A, lower-
left panels) and centralized concentrations of intracellular
TrkAI in NIH 3T3 transfectants (Fig. 1B, lower-left panel), con-
sistent with similar GN localization. Indirect IF also confirmed
similarity in the less-centralized intracellular expression of
TrkAIII in SH-SY5Y and NIH 3T3 transfectants (Fig. 1A, upper-
right panel, and B, bottom-right panel). Other than exhibiting
differences in nuclear morphology, TrkAI and TrkAIII NIH
3T3 transfectants did not differ appreciably in phase-contrast
morphology (Fig. 1B, middle two panels). We confirm our
previous report that TrkAI does not exhibit constitutive ty-
rosine phosphorylation in either SH-SY5Y or NIH 3T3 cells,
whereas TrkAIII exhibits constitutive tyrosine phosphorylation
in both SH-SY5Y and NIH 3T3 transfectants (44).
Ultracentrifugation-fractionated intracellular membranes from
stable TrkAI SH-SY5Y transfectants characterized by Western
blotting for the ER marker calnexin, cis-GN marker GM130,
trans-GN marker TGN46, ERGIC marker ERGIC53, and
coatamer vesicle markers COP I and COP II (Fig. 1C, left
panel) were subjected to TrkAI IP. As shown in Fig. 1D (left
panel), low levels of predominantly immature gp110 TrkAI
characterized calnexin-positive ER membranes, whereas rela-
tively higher levels of predominantly mature gp140 TrkAI
characterized calnexin-negative non-ER membranes positive
for ERGIC53, GM130, TGN46, COP I, and COP II. This
indicates that TrkAI is not retained within the ER but readily
exits to the ERGIC/GN/vesicle compartments in association
with gp140 TrkAI maturation.
TrkAIII immunoprecipitated from fractionated intracellular
SH-SY5Y membranes exhibited relatively high-level retention
and tyrosine phosphorylation within both calnexin-positive ER
TrkAIII (green) and tyrosine phosphorylation (red; pTry) (second panel), and calnexin (green) and tyrosine phosphorylation (red; pTyr) (third
panel) in representative interphase TrkAIII SH-SY5Y transfectants, plus a lack of merge between tyrosine phosphorylation (pTyr; not detected)
and kd-muTrkAIII (green) (fourth panel) in an interphase kd-muTrkAIII SH-SY5Y transfectant. The lower panels demonstrate merged (yellow/
orange) GM130 (green) and TGN46 (red) expression (leftmost panel), GM130 (green) and tyrosine phosphorylation (red; pTyr) (second panel),
TGN46 (green) and tyrosine phosphorylation (red; pTyr) (third panel), and ERGIC53 (green) and tyrosine phosphorylation (red; pTyr) (fourth
panel) in representative interphase TrkAIII SH-SY5Y transfectants. Bar ) 10 &m. (D) IP/Western blots demonstrating reduced TrkAIII tyrosine
phosphorylation relative to total TrkAIII and %-tubulin in extracts from TrkAIII SH-SY5Y transfectants synchronized in G2/M by detachment
(Det) or 16-h NZ treatment (NZ), compared to unsynchronized controls (Non-Syn Cont) and cells 6 h post-NZ release (cell cycle FACS analyses
are provided for each cell population in the lower panels). (E) RT-PCR/Southern blot (left panel) demonstrating predominant endogenous
TrkAIII over TrkAI/II mRNA expression in U251 compared to SH-SY5Y cells, plus an IP/Western blot (right panel) demonstrating predominant
endogenous TrkAIII expression in U251 cells and TrkAIII SH-SY5Y transfectants. (F) Indirect IF demonstrating endogenous TrkAIII expression
in nonstressed U251 cells (Con, green) and inhibition of endogenous TrkAIII expression by 7-day treatment with 10 &M TrkAIII-PNA
(Hoechst-stained nuclei are light blue). (G) Indirect IF demonstrating endogenous TrkAIII expression (green, upper and lower leftmost panels),
tyrosine phosphorylation (red; pTyr, upper and lower second panels); merged TrkAIII expression and tyrosine phosphorylation (orange/yellow,
upper and lower third panels) plus merged TrkAIII expression, tyrosine phosphorylation, and Hoechst-stained nuclei (light blue) (upper and lower
fourth panels) in untreated (Cont, upper panels) and 100 nM CEP-701-treated (CEP-701, lower panels) U251 cells. (H) IP/Western blots
demonstrating loss of TrkAIII carboxyl-terminal domain and GM130 but not mannosidase II immunoreactivity in purified ERGIC/GN membranes
incubated for 10 min at 4°C with chymotrypsin at the concentrations indicated.
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membranes and calnexin-negative non-ER membranes pos-
itive for ERGIC53, GM130, TGN46, and COP I/II (Fig. 1D,
right panel). Furthermore, TrkAIII associated with calnexin-
positive ER membranes coimmunoprecipitated the ER chap-
erones calnexin and Grp78/BiP (Fig. 1D, right panel) and
exhibited alternative folding with an additional 105-kDa
TrkAIII species detected under nonreducing conditions but not
under reducing conditions (Fig. 1E). TrkAIII expression, how-
ever, did not associate with constitutive alternative XBP-1
splicing (data not shown), indicating that TrkAIII does not
activate the Ire1% branch of the ER stress response (51).
TrkAIII in a cytoplasmic tk domain orientation exhibits inter-
phase-restricted, ER/ERGIC/GN-associated activation. In con-
trast to the case with TrkAI, which does not exhibit tyrosine
phosphorylation despite significant GN accumulation (Fig. 2A),
indirect IF using a general phosphotyrosine antibody (pTyr) de-
tected TrkAIII-associated tyrosine phosphorylation during inter-
phase and postcytokinesis but not during mitosis in SH-SY5Y
transfectants (Fig. 2B). TrkAIII-associated tyrosine phosphoryla-
tion detected by indirect IF during interphase was localized pri-
marily to vesicle-like structures at the center of the calnexin-
positive ER (Fig. 2C, third panel from the left on the top row) in
close, overlapping association with GM130, TGN46, and in par-
ticular, ERGIC53 (Fig. 2C, second, third, and fourth panels on
the bottom row). SH-SY5Y transfectants synchronized in G2/M
by detachment (by FACS, 88% G2/M, 2% G1, and 10% S phase)
and by 16-h NZ treatment (by FACS, 91% G2/M, 1.3% G1, and
7.7% S phase) also exhibited reduced TrkAIII tyrosine phosphor-
ylation compared to unsynchronized counterparts (by FACS,
65% G1, 14% G2, and 21% S phase) and 6 h following NZ release
(by FACS, 60% G1 and 40% G2/M), in IP/Western blots (Fig.
2D). In contrast to nonmutated TrkAIII, similar levels of in-
tracellular expression of kd-muTrkAIII were not associated
with tyrosine phosphorylation in SH-SY5Y cells (Fig. 2C,
pTyr/kd-muTrkAIII panel), confirming that TrkAIII-associated
tyrosine phosphorylation is TrkAIII tk dependent. Constitutive
expression of endogenous TrkAIII mRNA detected by RT-
PCR (Fig. 2E, left panel), as well as intracellular expression of
endogenous TrkAIII protein detected by Western blotting
(Fig. 2E, right panel) and indirect IF (Fig. 2F and G), charac-
terized nonstressed human neural U251 glioma cells. Indirect
IF detected TrkAIII-PNA (10 &M) inhibition of endogenous
TrkAIII expression by U251 cells (Fig. 2F). Endogenous
TrkAIII expression in U251 cells was associated with areas of
intracellular tyrosine phosphorylation (Fig. 2G, upper panels),
inhibited by 100 nM CEP-701 (Fig. 2G, lower panels). These
data indicate that interphase-restricted TrkAIII activity within
ER/ERGIC/GN-associated structures is not confined to con-
ditions of exogenous overexpression.
Chymotrypsin digestion of fractionated ERGIC/GN mem-
branes from TrkAIII SH-SY5Y transfectants eliminated mem-
brane-associated TrkAIII carboxyl terminal and GM130 but
not mannosidase II immunoreactivity (Fig. 2H). This indicates
a cytoplasmic orientation for the TrkAIII carboxyl terminus
containing the tk domain, as previously described for GN-
associated GM130 but not mannosidase II (52).
TrkAIII binding of !-tubulin is tk dependent and results in
recruitment to the centrosome. To further study TrkAIII tk
function, a kd-muTrkAIII expression vector bearing phenylal-
anine substitutions of tk loop tyrosines Y670, Y674, and Y675
was constructed and stably transfected into SH-SY5Y cells.
Like its nonmutated counterpart, 100-kDa kd-muTrkAIII ex-
hibited intracellular expression and not cell surface expression
in SH-SY5Y cells (Fig. 2C, fourth panel on the top row) but
did not exhibit constitutive tyrosine phosphorylation assessed
by indirect IF (Fig. 2C, compare second and fourth panels on
the top row) or IP/Western blotting (Fig. 3A, upper and middle
panels). In contrast to nonmutated TrkAIII, kd-muTrkAIII im-
munoprecipitated from stable SH-SY5Y transfectants did not
exhibit kinase activity in a rabbit muscle enolase kinase assay
(25), confirming that it corresponds to a kinase-dead allele
(Fig. 3A, lower panel).
In coimmunoprecipitation assays, TrkAIII coimmunopre-
cipitated #-tubulin from whole-cell extracts (Fig. 3B) and ul-
tracentrifugation-fractionated intracellular membranes from
TrkAIII SH-SY5Y transfectants (Fig. 3C, lower panels, middle
column). In contrast, nonphosphorylated TrkAI and kd-muTrkAIII
coimmunoprecipitated negligible levels of #-tubulin from
whole-cell extracts (Fig. 3B), levels below the threshold of
detection in ultracentrifugation-fractionated membranes (Fig.
3C, left and right columns). Tyrosine-phosphorylated TrkAIII
but not TrkAI or kd-muTrkAIII also copurified with #-tubulin-
positive sucrose density gradient ultracentrifugation-fraction-
ated centrosomes from respective stable transfectants (Fig.
3D), and #-tubulin coimmunoprecipitated TrkAIII from cen-
trosomes purified from TrkAIII transfectants (Fig. 3E). TrkAIII
tk involvement in #-tubulin binding, suggested by the negligible bind-
ing exhibited by nonphosphorylated TrkAI and kd-muTrkAIII, was
confirmed using CEP-701, which inhibited TrkAIII tyrosine
phosphorylation and binding of #-tubulin, and using the pro-
tein tyrosine phosphatase (PTPase) inhibitor sodium or-
thovanadate (1 mM), which stimulated TrkAIII tyrosine phos-
phorylation and binding of #-tubulin in coimmunoprecipitation
assays (Fig. 3F). A requirement for full ERGIC/GN assembly for
TrkAIII binding of #-tubulin was supported using the ERGIC/
GN-disrupting agent BFA (5 &g/ml) (43), which inhibited
TrkAIII tyrosine phosphorylation and binding of #-tubulin (Fig.
3F), and a role for Hsp90 was suggested using the Hsp90
inhibitor GA (1 &M) (33), which also reduced TrkAIII tyrosine
phosphorylation and binding of #-tubulin (Fig. 3F). Levels of
TrkAIII tyrosine phosphorylation and binding of #-tubulin
were not influenced by NGF-neutralizing antibody (1 &g/ml),
A2a adenosine receptor antagonist SCH58621 (0.1 &M) (8), or
c-Src inhibitor GCP77675 (28), following treatment for up to
16 h (data not displayed). The centrosome origin of #-tubulin
was confirmed by coimmunoprecipitation of centrosome-asso-
ciated Nedd-1 (24) but not GN-associated #-tubulin-binding
protein GMAP-210 (39) from centrosome preparations (Fig. 3E).
TrkAIII phosphorylates centrosome components. TrkAIII
at the centrosome (Fig. 4A) was confirmed to exhibit tk func-
tion in Western blotting, which detected differential tyrosine
phosphorylation of 100-kDa, 70-kDa, 60-kDa, 48-kDa, 38-kDa,
and 33-kDa centrosome-associated proteins in TrkAIII SH-
SY5Y transfectants compared to TrkAI SH-SY5Y transfec-
tants (Fig. 4B, compare lanes 1 and 3). These differences were
abrogated by overnight treatment of TrkAIII transfectants
with 100 nM CEP-701 (Fig. 4B, compare lanes 3 and 4), in
association with reduced levels of total and tyrosine-phosphor-
ylated TrkAIII relative to #-tubulin (Fig. 4B, lower panels,
compare lanes 3 and 4). CEP-701 treatment of TrkAI SH-
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FIG. 3. TrkAIII interacts with the centrosome. (A) IP/Western blots (top and middle panels) demonstrating constitutive tyrosine phosphory-
lation (pTyr) associated with TrkAIII but not TrkAI or kd-muTrkAIII immunoprecipitated from respective SH-SY5Y transfectants, plus a
representative rabbit enolase kinase assay (bottom panel) demonstrating phosphorylation of rabbit enolase by TrkAIII but not TrkAI or
kd-muTrkAIII imunoprecipitate. (B) IP/Western blots demonstrating TrkAIII coimmunoprecipitation of #-tubulin (# tub) but negligible TrkAI and
kd-muTrkAIII #-tubulin coimmunoprecipitations from respective SH-SY5Y transfectants (relative %-tubulin [% tub] levels are displayed as input
controls, and IgG levels in immunoprecipitates are displayed as a loading control). (C) IP/Western blots demonstrating TrkAIII but not TrkAI or
kd-muTrkAIII coimmunoprecipitation of #-tubulin from ultracentrifugation-fractionated nonnuclear membranes from respective SH-SY5Y trans-
fectants (relative %-tubulin levels are displayed as input controls, and IgG levels in immunoprecipitates are displayed as a loading control).
(D) Western blots demonstrating copurification of tyrosine-phosphorylated TrkAIII (middle panels) but not TrkAI (left panels) or kd-muTrkAIII
(right panels) with #-tubulin-positive sucrose density gradient-purified centrosomes from respective SH-SY5Y transfectants. (E) IP/Western blots
demonstrating #-tubulin coimmunoprecipitation of Nedd-1 and TrkAIII but not GMAP-210 from sucrose density gradient ultracentrifugation-
purified centrosomes (fraction 3) from TrkAIII SH-SY5Y transfectants. (F) IP/Western blots demonstrating relative changes in TrkAIII tyrosine
phosphorylation and coimmunoprecipitation of #-tubulin in whole-cell extracts from TrkAIII SH-SY5Y transfectants treated with 100 nM
CEP-701, 5 &g/ml BFA, 1 &M GA, or 1 mM sodium orthovanadate for the times indicated.
4819
 at Tem
ple University on Septem
ber 10, 2009 
m
cb.asm
.org
Downloaded from
 
SY5Y transfectants had little influence upon centrosome com-
ponent tyrosine phosphorylation (Fig. 4B, compare lanes 1 and
2). Of the differentially phosphorylated proteins, TrkAIII is
likely to represent the 100-kDa component. Differential phos-
phorylation of #-tubulin was not detected despite TrkAIII
binding (data not displayed). The remaining differentially
phosphorylated centrosome proteins remain to be identified.
TrkAIII increases Plk-4 levels at the centrosome. Increased
centrosome interaction with Plk-4 promotes rapid amplification
of centrosomes (18). TrkAIII promotion of Plk-4 interaction with
the centrosome was supported by (i) Plk-4 copurification with
#-tubulin-positive centrosome fractions from TrkAIII but not
pcDNA or stable TrkAI SH-SY5Y transfectants, determined
by Western blotting (Fig. 5A); (ii) the observation that TrkAIII
but not TrkAI coimmunoprecipitated both Plk-4 and #-tubulin
from whole-cell extracts (Fig. 5B); and (iii) the observation
that TrkAIII expression associated with an increased number
of TrkAIII SH-SY5Y transfectants (24.2% * 5.9%) exhibiting
punctiform perinuclear Plk-4 staining (Fig. 5C), compared to
pcDNA (11.8% * 5.8%) and TrkAI (8% * 2.9%) transfec-
tants (six experiments, each representing 100 observations; P
values of +0.005 for TrkAIII versus pcDNA and +0.001 for
TrkAIII versus TrkAI transfectants; Student’s t test) (Fig. 5D).
Plk-4 expression in kd-muTrkAIII transfectants was not as-
sessed.
TrkAIII promotes centrosome amplification. TrkAIII dereg-
ulation of centrosome duplication was confirmed by transient
TrkAIII expression in human GFP-centrin-expressing HeLa cells
(Fig. 6A) (34). In this model, GFP-centrin-expressing HeLa cells
exhibited background centrosome amplification (,2 GFP-cen-
trin-positive centrosomes per cell) in a mean (* standard de-
viation [SD]) of 12.5% * 2.9% of cells (four independent
experiments, each of 50 cells) (Fig. 6B, lane NT). Centrosome
amplification was not increased above the background by tran-
sient pcDNA transfection or transient TrkAI expression and
remained at 13.5% * 3.9% in pcDNA and 15.5% * 2.6% in
TrkAI transient transfectants (Fig. 6B, lanes pcDNA and
TrkAI, respectively). Transient TrkAIII expression signifi-
cantly elevated centrosome amplification to 44% * 8.3% in
TrkAIII-positive transfectants (P values of +0.0001 for TrkAIII
versus nontransfected and pcDNA- and TrkAI-transfected
counterparts; Student’s t test). This effect was abrogated in the
presence of 100 nM CEP-701 (17% * 2.9%) and 10 &M
TrkAIII-PNA (16.5% * 3.3%) (Fig. 6B, lanes TrkAIII CEP-
701 and TrkAIII!PNA, respectively) and was not detected
following transient expression of kd-muTrkAIII (15.1% *
1.5%) (Fig. 6B). Mean centrosome numbers per cell in tran-
sient TrkAIII-GFP-expressing HeLa cell transfectants were
not evaluated, due to the high levels of amplification detected,
which made accurate counting difficult (Fig. 6A, bottom pan-
els). These data show that TrkAIII promotes centrosome am-
plification.
Centrosome amplification in stably transfected cell lines, char-
acterized by more than two #-tubulin-positive centrosomes per
cell (Fig. 6C), was detected in 14.2% * 4.1% of stable pcDNA
SH-SY5Y transfectants, 13.2% * 4.62% of stable TrkAI SH-
SY5Y transfectants, and 16.2% * 2.8% of stable kd-muTrkAIII
SH-SY5Y transfectants and was significantly elevated to 31.8%*
5.8% in stable TrkAIII SH-SY5Y transfectants (six experiments,
each consisting of 100 cells) (P value of+0.001 for TrkAIII versus
pcDNA, TrkAI, and kd-muTrkAIII transfectants; Student’s t test)
(Fig. 6D).
The mean (* SD) number of centrosomes per cell for
TrkAIII transfectants was 3.59* 2.8, with 32% of cells exhibiting
,2 centrosomes. This was significantly elevated over the number
of stable TrkAI transfectants (2.54 * 1.64), with 15% of cells
exhibiting ,2 centrosomes per cell; pcDNA transfectants (2.5 *
1.6), with 14% of cells exhibiting ,2 centrosomes; and stable
kd-muTrkAIII transfectants (2.76 * 2.15), with 16% of cells ex-
FIG. 4. TrkAIII tk phosphorylates centrosome components. (A) In-
direct IF demonstrating TrkAIII (first panel from the left; green), #-tu-
bulin (# Tub) (second panel; red), and merged TrkAIII/#-tubulin expres-
sion (third panel; orange/yellow) in sucrose density gradient-purified
centrosomes (fraction 3) from TrkAIII SH-SY5Y transfectants. Bar) 10
&m. (B) Western blots demonstrating differential (red arrows) centro-
some component tyrosine phosphorylation (pTyr) in centrosomes purified
from untreated (Con; lane 1) and 100 nM CEP-701-treated TrkAI SH-
SY5Y transfectants (CEP; lane 2), compared to untreated (Con; lane 3)
and 100 nM CEP-701-treated TrkAIII SH-SY5Y transfectants (CEP;
lane 4). Lower panels demonstrate relative levels of Y490 tyrosine-phos-
phorylated TrkAIII, total TrkAIII, and #-tubulin in the centrosome
preparations.
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FIG. 5. TrkAIII increases Plk-4 levels at the centrosome. (A) Western blots demonstrating Plk4 and TrkAIII copurification with #-tubulin (#-Tub)-
positive centrosomes from TrkAIII but not TrkAI or pcDNA SH-SY5Y transfectants. (B) IP/Western blots demonstrating phosphorylated-TrkAIII
coimmunoprecipitation of #-tubulin and Plk-4 from TrkAIII but not pcDNA or TrkAI transfectant extracts (preimmune IgG controls are displayed, and
IgG levels in immunoprecipitates are shown as a loading control). (C) Indirect IF demonstrating high levels of perinuclear punctiform Plk-4 staining
(arrows) in TrkAIII transfectants compared to the levels in pcDNA and TrkAI SH-SY5Y transfectants. Bar) 10 &m. (D) Histogram demonstrating the
mean (* SD) percentages of pcDNA, TrkAI, and TrkAIII SH-SY5Y transfectants exhibiting punctiform perinuclear Plk-4 staining in six independent
experiments, each representing counts from 100 individual cells (an asterisk indicates a significant statistical difference).
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FIG. 6. TrkAIII induces centrosome amplification. (A) Indirect IF demonstrating GFP-centrin-positive centrosomes (green) in TrkAI (upper-
right panel)- and TrkAIII (lower-right panel)-transfected GFP-centrin-expressing HeLa cells, plus merged (yellow) TrkAI (red; upper-left panel)
or TrkAIII (red; lower-left panel), and GFP-centrin (green) expression in the same cells. Bar ) 10 &m. (B) Histogram of the mean (* SD)
percentages of GFP-centrin-expressing HeLa cells exhibiting centrosome amplification (,2 centrosomes per cell) following sham transfection
(NT) or transient transfection with empty pcDNA vector, transient expression of TrkAI or TrkAIII, transient TrkAIII expression in the presence
of 100 nM CEP-701 or 10 &M TrkAIII-PNA, or transient kd-muTrkAIII expression, in six independent experiments, each representing counts from
100 individual positive cells (an asterisk indicates a significant statistical difference). (C) Phase-contrast micrographs with overlapping #-tubulin IF
(green) plus Hoechst-stained chromatin (light blue) with #-tubulin IF (green) demonstrating normal centrosome numbers and chromosome
alignment in representative TrkAI SH-SY5Y transfectants (upper right and left panels, respectively) and abnormal #-tubulin-positive centrosomes
associated with aberrant chromosome alignment in representative TrkAIII SH-SY5Y transfectants (middle and lower panels). Bar ) 10 &m.
(D) Histograms demonstrating the mean (* SD) percentages of stable pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII SH-SY5Y transfectants and
stable pcDNA, TrkAI, and TrkAIII NIH 3T3 transfectants exhibiting ,2 centrosomes per cell, in six independent experiments, each representing
100 cells per cell line (an asterisk indicates a significant statistical difference). (E) Indirect IF demonstrating centrosome amplification in a
representative TrkAIII-transfected SH-SY5Y cell (bar ) 10 &m), showing a merge (orange/yellow; top panel and lower-right panel) of abnormal
#-tubulin (#-Tub)-positive centrosomes (red; lower-left panel) and a single Cep170-positive maternal centriole (green; lower-middle panel).
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hibiting ,2 centrosomes (P values of +0.001 for TrkAIII versus
both TrkAI and pcDNA transfectants and +0.02 for TrkAIII
versus kd-muTrkAIII transfectants; Student’s t test). Centrosome
amplification in NIH 3T3 cells was detected in 12% * 2.4% of
pcDNA transfectants and 15% * 3.2% of TrkAI transfectants
and significantly elevated to 37%* 6.4% in TrkAIII transfectants
(P value of +0.001 for TrkAIII versus both pcDNA and TrkAI
transfectants; Student’s t test) (Fig. 6D).
Centrosome amplification was confirmed in TrkAIII SH-
SY5Y transfectants by indirect IF detection of frequent mul-
tiple #-tubulin-positive centrosomes associated with a single
Cep170-positive maternal centriole (Fig. 6E) (14).
TrkAIII promotes genetic instability. Genetic instability was
assessed by evaluating abnormal mitotic spindle formation, alter-
ations in polyploid/aneuploid status, generation of multinuclear
cells, and formation of large anaplastic nuclei (11, 12).
Abnormal %-tubulin-positive mitotic spindles (Fig. 7A) were
detected in 8% * 2.6% of pcDNA SH-SY5Y transfectants,
9% * 3.9% of TrkAI SH-SY5Y transfectants, and 12.1% *
2.2% of kd-muTrkAIII transfectants, and the level was signifi-
cantly elevated to 26% * 4.3% for TrkAIII SH-SY5Y trans-
fectants (P value of +0.001 for TrkAIII versus pcDNA and
TrkAI transfectants; Student’s t test; six experiments, each
representing 100 mitotic spindle counts) (Fig. 7B). In NIH 3T3
transfectants, abnormal %-tubulin-positive mitotic spindles
were detected in 10%* 2.2% of pcDNA transfectants, 13%*
2.6% of TrkAI transfectants, and the level was significantly
elevated to 32% * 3.6% for TrkAIII transfectants (P + 0.001;
Student’s t test) (Fig. 7B).
Polyploidy, evaluated in 100 metaphase spreads per cell line
and characterized by more than 100 chromosomes per cell, was
detected in 3% * 0.32% of TrkAIII SH-SY5Y transfectants
but not in equivalent numbers of pcDNA, TrkAI, or kd-mu
TrkAIII transfectants (Fig. 7C, lanes J).
Metaphase spreads confirmed a significant difference in the
aneuploid status of TrkAIII SH-SY5Y transfectants, which
contained a mean (* SD) of 52.2* 24.8 chromosomes per cell
(range, 9 to 180), compared to those of pcDNA transfectants,
which contained a mean of 59.7 * 5.8 chromosomes per cell
(range, 40 to 70); TrkAI transfectants, which contained a mean
of 60.9 * 5.6 chromosomes per cell (range, 53 to 74); and
kd-muTrkAIII transfectants, which contained a mean of 60.3 *
8.6 chromosomes per cell (range, 50 to 70) (P values of +0.01
for TrkAIII versus pcDNA, TrkAI, and kd-muTrkAIII trans-
fectants; Mann-Whitney/Wilcoxon rank sum test) (Fig. 7C).
An increase in polyploidy and altered aneuploid status also
characterized stable TrkAIII NIH 3T3 transfectants. TrkAIII
NIH 3T3 transfectants contained a mean (* SD) of 98.8 *
57.3 chromosomes per cell (range, 9 to 300), compared to
pcDNA transfectants, which contained 64.1 * 6.53 chromo-
somes per cell (range, 46 to 72), and TrkAI transfectants,
which contained 66 * 7.79 chromosomes per cell (range, 46 to
89) (Fig. 7D).
The generation of multinuclear cells (Fig. 7E), as an index of
mitotic catastrophe, was assayed following 72 h of culture.
TrkAIII SH-SY5Y transfectants generated a population of
11.2% * 3.4% multinuclear cells, which was significantly ele-
vated over the 2.4% * 2.2% of multinuclear pcDNA transfec-
tants, 2.6% * 1.1% of multinuclear TrkAI transfectants, and
4.6% * 0.5% of multinuclear kd-muTrkAIII transfectants gen-
erated over the same 72-h period (four independent experi-
ments, each representing 100 observations; P values of +0.005
for TrkAIII versus pcDNA, TrkAI, and kd-muTrkAIII trans-
fectants; Student’s t test) (Fig. 7F). Stable TrkAIII NIH 3T3
transfectants also generated a population of 28% * 0.4% of
multinuclear cells, which represents a significantly elevation
over the 5% * 0.2% of multinuclear pcDNA and 6.3% *
0.22% of multinuclear TrkAI NIH 3T3 transfectants generated
(Fig. 7F).
Stable TrkAIII SH-SY5Y and NIH 3T3 transfectants exhib-
ited a range of nuclear shapes and sizes, including large ana-
plastic nuclei, far greater than both pcDNA- and TrkAI-trans-
fected counterparts (Fig. 7G). Stable kd-muTrkAIII NIH 3T3
transfectants were not available for this study.
TrkAIII increases SCE, anaphase DNA bridging, and
chromosome missegregation and alters separase interac-
tion with the centrosome. SCE (30 metaphase spreads per cell
line; Fig. 8A) was detected in a mean (* SD) of 13.6%* 6.8%
of chromosomes per cell in TrkAIII SH-SY5Y transfectants
(n ) 30), which was significantly elevated over that detected in
pcDNA (4.73% * 2.73%), TrkAI (5.8% * 2.04%), and kd-mu
TrkAIII (4.2% * 2.2%) transfectants (P values of +0.001 for
TrkAIII versus pcDNA, TrkAI, and kd-muTrkAIII transfec-
tants; Student’s t test).
DNA bridging was detected in 5.6% * 0.7% of anaphase
TrkAIII SH-SY5Y transfectants, which is significantly higher
than the corresponding percentages of pcDNA (0.5% *
0.3%), TrkAI (1.5% * 0.8%), and kd-muTrkAIII (2.3% *
0.3%) transfectants (Fig. 8B). Complete chromosome misseg-
regation (Fig. 8C) was detected in 3.6% * 0.5% of TrkAIII
SH-SY5Y transfectants but not in equivalent numbers of
pcDNA, TrkAI, or kd-muTrkAIII transfectants (four experi-
ments, each representing 100 observations) (Fig. 8D).
Indirect IF detected normal patterns of separase-centrosome
interaction during prometaphase through late metaphase but not
anaphase through telophase (Fig. 8E) in relatively more pcDNA
and TrkAI transfectants than TrkAIII SH-SY5Y transfectants
(Fig. 8E and F). Lack of separase-centrosome interaction (Fig.
8F) was detected in 67.9% * 9.9% of metaphase TrkAIII SH-
SY5Y transfectants, compared to 25.4% * 6.4% of pcDNA-
transfected counterparts, 24.7% * 9.1% of TrkAI-transfected
counterparts, and 25.3% * 4.6% of kd-muTrkAIII-transfected
counterparts (four experiments, each representing 100 observa-
tions per cell line; P values of+0.001 for TrkAIII versus pcDNA,
TrkAI, and kd-muTrkAIII; Student’s t test) (Fig. 8G). These data
suggest that TrkAIII impedes separase interaction and function at
the centrosome.
TrkAIII-PNA. TrkAIII–PNA–D-(AAKK)4 conjugate (10
&M) inhibited TrkAIII but not TrkAI protein expression in
respective SH-SY5Y transfectants following 14-day treatment,
as detected by Western blotting (Fig. 9A) and indirect IF (Fig.
9C, upper panels). In [3-(4,5-dimethylthiazol-2yl)-5(3-carboxy-
methonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS)
proliferation assays, TrkAIII transfectants but not pcDNA or
stable TrkAI SH-SY5Y transfectants treated for 14 days with
10 &M TrkAIII-PNA exhibited a significant 20.8% reduction
(P + 0.05; Student’s t test) in proliferation (Fig. 9B). TrkAIII-
PNA also reversed the highly lobular anaplastic nuclear phe-
notype exhibited by TrkAIII but not TrkAI SH-SY5Y trans-
fectants (Fig. 9C). These data confirm TrkAIII-PNA as a
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FIG. 7. TrkAIII promotes genetic instability in SH-SY5Y cells. Asterisks indicate significant statistical differences. (A) Indirect IF demon-
strating %-tubulin-positive (red) normal, tripolar, and multipolar mitotic spindles in SH-SY5Y transfectants. Bar ) 10 &m. (B) Histograms
demonstrating the mean (* SD) percentages of mitotic pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII SH-SY5Y transfectants and mitotic pcDNA,
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specific inhibitor of TrkAIII expression and implicate TrkAIII
in regulating proliferation and anaplastic nuclear morphology
in SH-SY5Y cells.
DISCUSSION
We report an important novel function for the alternative
TrkAIII splice variant as an inducer of centrosome amplifica-
tion and promoter of genetic instability. This function depends
upon the intracellular TrkAIII retention, accumulation, and
spontaneous interphase-restricted activation, in a cytoplasmic
tk domain orientation, within membranes that closely associate
with the fully assembled ER/ERGIC/GN compartment. TrkAIII
activated within this novel membrane-substrate context is reg-
ulated by endogenous PTPase activity, GA-sensitive interac-
tion with Hsp90, and ERGIC/GN assembly status and acquires
the capacity to bind #-tubulin, resulting in recruitment to the
centrosome. This causes differential phosphorylation of several
centrosome-associated components, increases centrosome in-
teraction with Plk-4, and decreases centrosome interaction
with separase, leading to centrosome amplification and in-
creased genetic instability.
The spontaneous activation of intracellular TrkAIII de-
tected in stably transfected SH-SY5Y and NIH 3T3 cell lines
(44), combined with TrkAIII function in human HeLa cells
and endogenous TrkAIII-associated tyrosine phosphorylation
in human neural U251 glioma cells, confirms that TrkAIII
activation is not cell type or clone specific or confined to
conditions of overexpression. However, since alternative TrkAIII
splicing is stress regulated in NB cells (44), TrkAIII activity is
regulated by endogenous PTPases and interaction with Hsp90
(this study), and the outcome of TrkAIII-induced centrosome
amplification is likely to depend upon oncosuppressor status
(6, 7, 35, 40, 42, 49, 53), the effect of TrkAIII expression upon
cell behavior is likely to exhibit some degree of cell specificity.
TrkAIII intracellular accumulation, caused by exon 6 and
7 skipping and associated with complete impediment of cell
surface translocation (unpublished data), is likely to depend
upon the omission of N-glycosylation sites within exons 6
and 7, which have been implicated in TrkA cell surface
expression (44, 48), and is consistent with reports that re-
duced N-glycosylation promotes receptor tk intracellular en-
trapment (5, 13, 46).
The high-level ER retention exhibited by TrkAIII indicates
difficulty in overcoming ER quality control, supported by al-
ternative folding and constitutive binding of calnexin and
Grp78/BiP exhibited by ER-associated TrkAIII. TrkAIII also
accumulates within non-ER membranes in association with the
loss of alternative folding and calnexin and Grp78/BiP binding,
indicating eventual ER quality control satisfaction. TrkAIII
SH-SY5Y transfectants, however, do not exhibit constitutive
alternative splicing of the ER stress response transcription
factor XBP-1, indicating that TrkAIII ER perturbation is be-
low the threshold for activation of the Ire1% branch of the ER
stress response (51).
TrkAIII tyrosine phosphorylation, detected in ER and
non-ER membranes, was localized by indirect IF primarily to
perinuclear vesicle-like structures at the center of the calnexin-
positive ER that closely associate with and overlap GM130,
TGN46, and, in particular, ERGIC-53 expression, suggesting
relative restriction to structures associated with the assembled
ERGIC/GN. This was supported using the ERGIC/GN-dis-
rupting agent BFA (43), which abrogated TrkAIII tyrosine
phosphorylation. The observation that TrkAIII-associated ty-
rosine phosphorylation does not occur throughout the calnexin-
positive ER may not only depend upon alternative TrkAIII
folding and TrkAIII binding of GRP78/BiP, which inactivates
ER-associated receptor tks (20), but also endogenous ER-
associated PTPase activity (10), as suggested by sodium or-
thovanadate stimulation of TrkAIII tyrosine phosphorylation.
The localization of TrkAIII-associated tyrosine phosphoryla-
tion to the center of the calnexin-positive ER suggests that
conditions favorable for TrkAIII activity within the ER lie
adjacent to the ERGIC/GN, which would include both ER exit
sites and anterograde COP II transport vesicles (1).
The possibility that TrkAIII-associated tyrosine phosphory-
lation represents an artifact of overexpression is diminished by
the observations that significant intracellular TrkAI accumu-
lation within the GN and that similar intracellular levels of
kd-muTrkAIII did not associate with tyrosine phosphorylation
and by endogenous TrkAIII-associated tyrosine phosphoryla-
tion in human neural U251 glioma cells. U251 cells were cho-
sen to study endogenous TrkAIII, as they exhibit constitutive
predominant endogenous TrkAIII expression under normal
conditions. This is in contrast to NB cells that exhibit stress-
induced and not constitutive endogenous TrkAIII expression
(44, 45; this study), which complicates the study of endogenous
TrkAIII behavior due to the collateral effects associated with
cellular stress. Intracellular endogenous TrkAIII expression by
U251 cells was inhibited by TrkAIII-PNA, confirming its identity,
and was associated with intracellular tyrosine phosphorylation,
which was inhibited by the pan-Trk tk inhibitor CEP-701 (4). This
indicates that TrkAIII-associated tyrosine phosphorylation is not
restricted to conditions of overexpression and sustains our
TrkAI, and TrkAIII NIH 3T3 transfectants exhibiting abnormal (tripolar, multipolar, and pseudobipolar) spindles in six independent experiments,
each representing 100 individual cells. (C) Histograms of the percentages of pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII SH-SY5Y transfectants
containing 1 to 9 (column A), 10 to 19 (column B), 20 to 29 (column C), 30 to 39 (column D), 40 to 49 (column E), 50 to 59 (column F), 60 to
69 (column G), 70 to 79 (column H), 80 to 89 (column I), and ,100 (column J) chromosomes in 100 metaphase spreads for each cell line, plus
mean (* SD) chromosome numbers per cell line. (D) Histograms, containing representative metaphase chromosome spreads (inserts), demon-
strating chromosome number distribution in 100 metaphase spreads in pcDNA, TrkAI, and TrkAIII NIH 3T3 transfectants. (E) Light micrographs
of polynuclear TrkAIII SH-SY5Y transfectants. Bar ) 10 &m. (F) Histograms demonstrating the mean (* SD) percentages of multinuclear cells
(!2 nuclei per cell) generated following 72-h culture of equal numbers of pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII SH-SY5Y transfectants and
pcDNA, TrkAI, and TrkAIII NIH 3T3 transfectants in six independent experiments, each representing 100 individual cells. (G) Representative
Hoechst fluorescence demonstration of typical nuclear shapes and sizes exhibited by pcDNA-, TrkAI-, and TrkAIII-transfected SH-SY5Y cells and
pcDNA, TrkAI, and TrkAIII NIH 3T3 transfectants. Bar ) 10 &m.
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hypothesis that constitutive TrkAIII activation results primar-
ily from intracellular entrapment caused by reduced extracel-
lular domain N glycosylation (48) and subsequent ligand-inde-
pendent activation facilitated by omission of the extracellular
Ig C1 domain within alternatively spliced exons 6 and 7 (2).
TrkAIII-associated tyrosine phosphorylation was detected
during interphase, inhibited during mitosis, and reactivated
postcytokinesis, confirming cell cycle regulation. This is likely
to depend upon cell cycle-regulated PTPases (10, 32), sup-
ported by sodium orthovanadate stimulation of TrkAIII ty-
rosine phosphorylation and also upon cycles of ERGIC/GN
disruption and reassembly (15), supported by BFA (43) inhi-
bition of TrkAIII tyrosine phosphorylation. Furthermore, in-
hibitor studies demonstrating CEP-701 and BFA inhibition of
TrkAIII tyrosine phosphorylation and sodium orthovanadate
stimulation of TrkAIII tyrosine phosphorylation but no effect
of NGF-neutralizing antibody, A2a adenosine receptor antag-
onist, and c-Src inhibitor indicate that TrkAIII activation dif-
fers from both ligand-dependent activation of mature cell sur-
face TrkA (TrkAI/TrkAII) and A2a adenosine receptor/c-Src-
mediated activation of immature GN-associated TrkA (TrkAI/
TrkAII) (37) in being spontaneous, ligand independent, Trk tk
mediated, and dependent upon full ER/ERGIC/GN assembly.
A cytoplasmic orientation for the active TrkAIII tk domain
within internal ER/ERGIC/GN membranes, confirmed by chy-
motrypsin digestion as described for GN-associated GM130
but not mannosidase II (52), would place TrkAIII activity in
close proximity to the centrosome (38). Indeed, TrkAIII inter-
action with the centrosome was confirmed by the observations
that (i) TrkAIII but not TrkAI- or kd-muTrkAIII-bound #-tu-
bulin, (ii) tyrosine-phosphorylated TrkAIII but not TrkAI or
kd-muTrkAIII copurified with #-tubulin-positive centrosomes,
and (iii) #-tubulin coimmunoprecipitated TrkAIII from puri-
fied centrosome preparations. TrkAIII tk involvement in this
interaction, suggested by the lack of #-tubulin binding exhib-
ited by nonphosphorylated TrkAI and kd-muTrkAIII, was sup-
ported by CEP-701 inhibition of TrkAIII tyrosine phosphory-
lation and #-tubulin binding and by sodium orthovanadate
stimulation of TrkAIII tyrosine phosphorylation and #-tubulin
binding. The requirement for full ERGIC/GN assembly for
this interaction was also supported by BFA inhibition of
TrkAIII tyrosine phosphorylation and #-tubulin binding, and a
role for Hsp90 was suggested by GA (33) inhibition of TrkAIII
tyrosine phosphorylation and #-tubulin binding. These data
indicate that TrkAIII exhibits a unique binding interaction
with #-tubulin, dependent upon druggable PTPase-regulated
and Hsp90-dependent TrkAIII tk activity within the context of
full ER/ERGIC/GN assembly.
TrkAIII tk function at the centrosome was confirmed by
the differential tyrosine phosphorylation of several centro-
some-associated components in TrkAIII SH-SY5Y transfec-
tants compared to TrkAI SH-SY5Y transfectants and was
reversed by the pan-Trk inhibitor CEP-701 (4). This indi-
cates that TrkAIII alters the kinase/phosphate equilibrium
at the centrosome. Of these differentially phosphorylated com-
ponents, the 100-kDa protein is likely to represent TrkAIII,
whereas the remaining 70-kDa, 60-kDa, 48-kDa, 38-kDa, and
33-kDa components remain to be identified. Consistent with
TrkAIII tk function at the centrosome, transient TrkAIII ex-
pression in GFP-centrin-expressing HeLa cells deregulated
centrosome duplication, resulting in centrosome amplification
(34). This effect was not observed following transient pcDNA,
TrkAI, or kd-muTrkAIII transfection and was inhibited by
CEP-701 and TrkAIII-PNA, confirming dependence upon
TrkAIII expression and TrkAIII tk activity. Increased levels of
centrosome amplification, confirmed by the presence of mul-
tiple centrosomes containing a single Cep170-positive mater-
nal centriole (14), also characterized TrkAIII SH-SY5Y and
NIH 3T3 stable transfectants but not pcDNA- and TrkAI-
transfected counterparts, further confirming that TrkAIII pro-
motes centrosome amplification. Potential mechanisms
through which TrkAIII promotes centrosome amplification in
addition to altering the kinase/phosphate equilibrium that
tightly regulates centrosome duplication (27) include TrkAIII
promotion of Plk-4 interaction with the centrosome, reported
to induce rapid centrosome amplification (18), and TrkAIII
impairment of separase interaction with the centrosome, also
reported to result in centrosome amplification (41, 47).
Increased genetic instability associated with centrosome am-
plification, characterized by increased abnormal mitotic spin-
dle formation, altered polyploid/aneuploid status, increased
generation of multinuclear cells, and a wide range of nuclear
shapes and sizes, including large anaplastic nuclei (11, 12), was
detected in TrkAIII transfectants but not pcDNA, TrkAI, or
FIG. 8. TrkAIII reduces separase interaction at the centrosome. (A) Representative SCE assay demonstrating SCE in a TrkAIII SH-SY5Y
transfectant (circled panel), with aligned chromosomes, chromosome numbers (Chrom), and SCE percentage presented (boxed panel), plus a
histogram demonstrating the mean (* SD) percentage of SCE in 30 metaphase spreads per pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII SH-SY5Y
cell lines (an asterisk indicates a significant statistical difference). (B) Fluorescence micrograph (insert) demonstrating anaphase DNA bridging in
a representative TrkAIII SH-SY5Y transfectant plus a histogram of the mean (* SD) percentages of pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII
SH-SY5Y transfectants exhibiting anaphase DNA bridging (six independent experiments, each representing 100 observations per cell line).
(C) Phase-contrast and overlapping fluorescence micrographs demonstrating chromosome missegregation in representative TrkAIII SH-SY5Y
transfectants (bar ) 10 &m) plus evidence of continuous DNA strands with micronuclei (arrows) linking two TrkAIII SH-SY5Y transfectants
postcytokinesis. (D) Histogram demonstrating the mean (* SD) percentages of mitotic pcDNA, TrkAI, TrkAIII, and kd-muTrkAIII SH-SY5Y
transfectants exhibiting chromosome missegregation in six independent experiments, each representing 100 observations per cell line. (E) Indirect
IF demonstrating normal #-tubulin (#-tub) (red; left panels), merged #-tubulin (red)/separase (Sep) (green) expression (middle panels) plus
Hoechst stained chromatin (chr) (light blue; right panels) in representative prometaphase-through-telophase TrkAI SH-SY5Y transfectants.
(F) Indirect IF demonstrating abnormal #-tubulin expression (red; left panels), merged #-tubulin (red)/separase (green) expression (middle
panels), and Hoechst-stained chromatin (light blue; right panels) in representative mitotic TrkAIII SH-SY5Y transfectants. Bar ) 10 &m.
(G) Histogram of the mean (* SD) percentages of pcDNA, TrkAI, TrkAIII and kd-muTrkAIII SH-SY5Y transfectants exhibiting a lack of
separase/#-tubulin association during metaphase in six independent experiments, each representing 100 observations per cell line (an asterisk
indicates a significant statistical difference).
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kd-muTrkAIII transfectants, confirming dependence upon
TrkAIII expression and TrkAIII tk activity. TrkAIII transfectants
but not pcDNA, TrkAI, or kd-muTrkAIII transfectants also ex-
hibited increased chromosome missegregation and anaphase
DNA bridging, associated with impaired centrosome associa-
tion with separase, reported to result in similar manifestations
(41, 47), and exhibited increased levels of SCE, suggesting
elevated levels of homologous recombination and/or an ele-
vated burden of single-strand DNA breaks similar to that re-
ported for JAK2 oncogenic tk (36).
TrkAIII promotion of centrosome amplification and genetic
instability is associated with more malignant behavior, charac-
terized by TrkAIII induction of NIH 3T3 tumorigenic activity
and promotion of SH-SY5Y primary and metastatic xenograft
tumorigenic activity (44, 45). It should be noted, however, that
centrosome amplification in normal cells may act as a backup
to the mitotic spindle checkpoint, promoting mitotic catastro-
phe and oncosuppressor-mediated senescence and/or apopto-
sis (21, 53). This suggests that tumor suppressor inactivation
may be a prerequisite for the oncogenic effect of TrkAIII
detected in SH-SY5Y and NIH 3T3 cells. This is supported by
reports that link p53, adenomatous polyposis coli gene, and
ATM inactivation to centrosome amplification and subsequent
oncogenesis (7, 40, 49), and these results sustain the associa-
tion between centrosome amplification and tumor malignancy
and support the hypothesis that centrosome amplification
FIG. 9. PNA knockdown of TrkAIII expression. (A) Western blots demonstrating inhibition of TrkAIII but not TrkAI or %-tubulin (%-Tub)
expression in TrkAIII and TrkAI SH-SY5Y transfectants (Con) treated for 14 days with 10 &M TrkAIII-PNA. (B) Line graphs demonstrating
significant inhibition (*) of TrkAIII but not pcDNA or TrkAI SH-SY5Y transfectant proliferation in 2-day MTS proliferation assays initiated 14
days following treatment with or without (control) 10 &M TrkAIII PNA (mean * SD MTS reagent absorbance [Abs] at 492 nm, in duplicate
experiments performed using six cultures per cell line per time point). (C) Indirect IF demonstrating the inhibitory effect of 14-day treatment with
10 &M TrkAIII-PNA upon TrkAIII (green; upper-left two panels, control versus TrkAIII-PNA) but not TrkAI (green; upper-right two panels,
control versus TrkAIII-PNA) expression plus the effect of 14-day treatment with 10 &M TrkAIII-PNA upon Hoechst-stained lobular nuclear
morphology in TrkAIII (blue; lower-left two panels, control versus TrkAIII-PNA) but not TrkAI (lower-right two panels, control versus
TrkAIII-PNA) SH-SY5Y transfectants.
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represents a fundamental oncogenic mechanism (11, 12, 26,
35, 49).
In support of our hypothesis that TrkAIII represents an
important and potentially druggable target in NB, we identified
the pan-Trk inhibitor CEP-701 (4) as an inhibitor of TrkAIII tk
activity, TrkAIII binding of #-tubulin, and TrkAIII induction
of centrosome amplification; the ERGIC/GN-disrupting agent
BFA (43) and the Hsp90 inhibitor GA (33) as inhibitors of
TrkAIII tk activity and binding of #-tubulin; and a novel TrkAIII-
PNA as a specific inhibitor of TrkAIII expression, TrkAIII-in-
duced centrosome amplification, TrkAIII transfectant prolifera-
tion, and TrkAIII-induced anaplastic lobular nuclear morphology.
We are currently developing novel TrkAIII-PNA formulations
to optimize uptake and targeting and reduce inhibitory con-
centrations for future use, in combination with inhibitors of
TrkAIII tk activity in NB models in vivo.
In conclusion, we characterize TrkAIII as a novel and rare
example of an intracellular membrane-associated oncogenic tk
that targets the centrosome, induces centrosome amplification,
and promotes genetic instability. We propose that this novel
function, facilitated by spontaneous ligand-independent acti-
vation within the context of a fully assembled ER/ERGIC/GN
compartment, results in acquisition of #-tubulin-binding activ-
ity and TrkAIII recruitment to the centrosome. This in turn
alters the kinase/phosphate equilibrium at the centrosome and
increases Plk-4 but reduces separase interaction with the cen-
trosome, leading to centrosome amplification and promotion
of genetic instability. This unveils an important and novel al-
ternative mechanism to “classical” cell surface oncogenic re-
ceptor tk signaling (3), through which TrkAIII and potentially
other oncogenic tk receptors that localized in an active form to
intracellular membranes (13, 50) exert oncogenic activity.
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